Accordingly, we suggest that CRBN may serve as a potential target for enhancing homeostatic sleep pressure to treat insomnia and decreasing pathologic proteins to prevent neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The gene discussed is CRBN; the disease is early-onset autosomal dominant Alzheimer disease.